Kadar Hemoglobin Pada Pasien Diabetes Melitus Tipe 2 Berdasarkan Stadium Nefropati Diabetik Dalam Skrining Kejadian Anemia

Desyani Ariza; Amirah; Andi Maya Kesrianti

doi:10.62027/praba.v3i4.609

Authors

Desyani Ariza Universitas Megarezky, Makassar, Indonesia
Amirah Universitas Megarezky, Makassar, Indonesia
Andi Maya Kesrianti Universitas Megarezky, Makassar, Indonesia

DOI:

https://doi.org/10.62027/praba.v3i4.609

Keywords:

Hemoglobin, Anemia, Diabetic Nephropathy

Abstract

Diabetes Mellitus often causes disorders in other organs, one of which is kidney disorders, commonly known as Diabetic Nephropathy. Diabetic Nephropathy (DN) is a chronic microvascular complication of Diabetes Mellitus, which is the main cause of end-stage kidney disease. Decreased hemoglobin (Hb) levels, or anemia, are very common clinical manifestations found in patients with this impaired kidney function. Pathophysiologically, the decrease in hemoglobin in DN patients is multifactorial, involving absolute or relative erythropoietin (EPO) deficiency due to damage to renal peritubular interstitial cells. As a result, there is a significant disruption of erythropoiesis, which can disrupt the process of red blood cell maturation in the hematopoiesis process. Monitoring hemoglobin levels is a crucial parameter because anemia in this DN population often appears earlier and is more severe than in non-diabetic chronic kidney disease patients. Therefore, early identification of fluctuations in hemoglobin levels is crucial in clinical management to prevent worsening of the systemic condition of patients with Diabetic Nephropathy. This study aims to review Hemoglobin levels in Type 2 Diabetes Mellitus Patients Based on Diabetic Nephropathy Stage in Anemia Screening. The method in this study used Descriptive Analytical with a sample of 47 respondents who met the inclusion criteria. The sampling and research location were conducted at Dr. Wahidin Sudirohusodo Hospital, Makassar. Hemoglobin measurements were measured using Sysmex Series XN-1000 with the Flowcytometry tool method. The results of the study found normal Hb levels (not anemic) in 25 respondents (53.20%), Mild Anemia in 6 respondents (12.80%), Moderate Anemia in 13 respondents (27.60%) and Severe Anemia in 3 respondents (6.40%). From these data, it is known that not all Diabetic Nephropathy patients in this study experienced Anemia.

References

Adane, A., Abate, M., & Bitew, Z. W. (2020). Prevalence and associated factors of anemia among diabetic patients at a tertiary hospital in Ethiopia. Scientific Reports, 10(1), 20546. https://doi.org/10.1038/s41598-020-77627-2.

Al-Kuraishy, H. M., Al-Gareeb, A. I., & Al-Niemi, M. S. (2021). Erythropoietin resistance and oxidative stress in patients with diabetic nephropathy: A contemporary review. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15(4), 102187. https://doi.org/10.1016/j.dsx.2021.06.012.

American Diabetes Association. (2023). Chronic kidney disease and risk management: Standards of care in diabetes—2023. Diabetes Care, 46(Supplement_1), S191-S202. https://doi.org/10.2337/dc23-S009.

Hanafi, M., & Setyohadi, B. (2021). Pathophysiology of anemia in chronic kidney disease: The role of inflammation and iron metabolism. Indonesian Journal of Internal Medicine, 53(2), 188-195.

International Diabetes Federation. (2021). IDF Diabetes Atlas (10th ed.). Brussels, Belgium: International Diabetes Federation.

Kidney Disease: Improving Global Outcomes (KDIGO). (2024). KDIGO 2024 Clinical Practice Guideline for the Management of Diabetes and Chronic Kidney Disease. Kidney International, 105(1), S1-S120. https://doi.org/10.1016/j.kint.2023.09.012.

Kurniawan, A., Sinto, R., & Mansyur, M. (2022). Correlation between renal function and hemoglobin levels in patients with diabetic nephropathy: A cross-sectional study. Journal of Diabetes and Its Complications, 36(4), 108-115.

Nugroho, P., & Pratama, A. (2023). Role of hepcidin and chronic inflammation in the development of anemia in diabetic kidney disease. Indonesian Journal of Internal Medicine, 55(2), 245-253.

Persatuan Endokrinologi Indonesia (PERKENI). (2021). Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2021. PB PERKENI.

Singer, R. F., & Navaneethan, S. D. (2021). Anemia in Diabetic Kidney Disease: Deepening Our Understanding. Current Diabetes Reports, 21(11), 45. https://doi.org/10.1007/s11892-021-01412-x.

Thomas, M. C., & Cooper, M. E. (2021). Pathogenesis of diabetic nephropathy and its complications. Nature Reviews Nephrology, 17(10), 651-665.

Tuttle, K. R., et al. (2022). Diabetic Kidney Disease: A Report From an ADA Consensus Conference. Diabetes Care, 45(7), 1663-1674. https://doi.org/10.2337/dci22-0012.

Zaman, S., Rafique, S., & Jahan, I. (2022). Prevalence of anemia in different stages of diabetic nephropathy among type 2 diabetes mellitus patients. Journal of Diabetes and Endocrinology, 14(1), 12-25. https://doi.org/10.5897/JDE2022.0154.

Zhuang, X., Jiao, B., & Li, S. (2023). Hemoglobin levels as a predictor of renal outcomes in patients with type 2 diabetes and chronic kidney disease. Frontiers in Endocrinology, 14, 112-128.at inflamasi sistemik pada pasien tersebut.